Loading…
Time trends in uptake rates of risk-reducing mastectomy in Israeli asymptomatic BRCA1 and BRCA2 mutation carriers
Background The rate of risk-reducing bilateral mastectomy (RRBM) among cancer-free Israeli female BRCA1/BRCA2 mutation carriers was reportedly 13% in 2010. Current RRBM rates in Israel and factors seemingly associated with opting for RRBM were reevaluated. Methods Israeli female cancer-free BRCA1/BR...
Saved in:
| Published in: | Breast cancer research and treatment 2021, Vol.185 (2), p.391-399 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c388z-5d3fe7e1086a43f7949b1b442719bac42fb82cb008606d91d60208a770d9f6dc3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c388z-5d3fe7e1086a43f7949b1b442719bac42fb82cb008606d91d60208a770d9f6dc3 |
| container_end_page | 399 |
| container_issue | 2 |
| container_start_page | 391 |
| container_title | Breast cancer research and treatment |
| container_volume | 185 |
| creator | Galmor, Lee Bernstein-Molho, Rinat Sklair-Levy, Miri Madoursky-Feldman, Dana Zippel, Dov Laitman, Yael Friedman, Eitan |
| description | Background
The rate of risk-reducing bilateral mastectomy (RRBM) among cancer-free Israeli female
BRCA1/BRCA2
mutation carriers was reportedly 13% in 2010. Current RRBM rates in Israel and factors seemingly associated with opting for RRBM were reevaluated.
Methods
Israeli female cancer-free
BRCA1/BRCA2
mutation carriers, who were followed at the high-risk clinic at Sheba Medical Center between January 2011 and April 2020 were eligible. Univariate Cox regression and log-rank test were used to study the crude association between potential predictors and performance of RRBM.
Results
Overall, 427 cancer-free
BRCA1
(
n
= 218) or
BRCA2
(
n
= 209) mutation carriers were included. Median age at genotyping was 33.6 years (interquartile range 26.8–41.8 years), median follow-up 4.4 years (range 0.1–7.6 years). Overall, 41/427 (9.6%) participants underwent RRBM, all of them within 5 years of genotyping. Being married (HR-2.57,
p
= 0.017) and having a first degree relative with breast cancer (BC) (HR-2.19,
p
= 0.017) were positively associated with RRBM, whereas any previous benign breast biopsy was negatively associated (HR-0.48,
p
= 0.029) with performing RRBM.
Conclusions
RRBM is still infrequently elected by Israeli
BRCA1/BRCA2
mutation carriers, with married women with one relative with BC who have not undergone previous breast biopsy more likely to opt for RRBM. |
| doi_str_mv | 10.1007/s10549-020-05949-z |
| format | article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2447838327</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A651058470</galeid><sourcerecordid>A651058470</sourcerecordid><originalsourceid>FETCH-LOGICAL-c388z-5d3fe7e1086a43f7949b1b442719bac42fb82cb008606d91d60208a770d9f6dc3</originalsourceid><addsrcrecordid>eNp9kt9rFDEQxxdR7Fn9B3yQgCC-bM2P3ST7eB5qC4VCqc8hm8xe0-4m1yT7cPfXm-tV24pIHjLMfL5DZvKtqvcEnxCMxZdEcNt0Naa4xm1Xot2LakFawWpBiXhZLTDhouYS86PqTUo3GONO4O51dcRYiZloF9XdlZsA5QjeJuQ8mjdZ3wKKOkNCYUDRpds6gp2N82s06ZTB5DBt9-xZihpGh3TaTpuS1NkZ9PVytSRIe3sfUTTNueSDR0bH6CCmt9WrQY8J3j3cx9XP79-uVqf1-cWPs9XyvDZMyl3dWjaAAIIl1w0bRJmvJ33TUEG6XpuGDr2kpseljrntiOVlD1ILgW03cGvYcfX50HcTw90MKavJJQPjqD2EOSnaNEIyyago6Me_0JswR19eVyjJpWy4oI_UWo-gnB9Cjtrsm6olb8tfyEbgQp38gyrHwuRM8DC4kn8m-PREcA16zNcpjPN-aek5SA-giSGlCIPaRDfpuFUEq70h1MEQqixC3RtC7Yrow8Nocz-B_SP57YACsAOQSsmvIT7O_p-2vwAe5L4G</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2486884672</pqid></control><display><type>article</type><title>Time trends in uptake rates of risk-reducing mastectomy in Israeli asymptomatic BRCA1 and BRCA2 mutation carriers</title><source>Springer Link</source><creator>Galmor, Lee ; Bernstein-Molho, Rinat ; Sklair-Levy, Miri ; Madoursky-Feldman, Dana ; Zippel, Dov ; Laitman, Yael ; Friedman, Eitan</creator><creatorcontrib>Galmor, Lee ; Bernstein-Molho, Rinat ; Sklair-Levy, Miri ; Madoursky-Feldman, Dana ; Zippel, Dov ; Laitman, Yael ; Friedman, Eitan</creatorcontrib><description>Background
The rate of risk-reducing bilateral mastectomy (RRBM) among cancer-free Israeli female
BRCA1/BRCA2
mutation carriers was reportedly 13% in 2010. Current RRBM rates in Israel and factors seemingly associated with opting for RRBM were reevaluated.
Methods
Israeli female cancer-free
BRCA1/BRCA2
mutation carriers, who were followed at the high-risk clinic at Sheba Medical Center between January 2011 and April 2020 were eligible. Univariate Cox regression and log-rank test were used to study the crude association between potential predictors and performance of RRBM.
Results
Overall, 427 cancer-free
BRCA1
(
n
= 218) or
BRCA2
(
n
= 209) mutation carriers were included. Median age at genotyping was 33.6 years (interquartile range 26.8–41.8 years), median follow-up 4.4 years (range 0.1–7.6 years). Overall, 41/427 (9.6%) participants underwent RRBM, all of them within 5 years of genotyping. Being married (HR-2.57,
p
= 0.017) and having a first degree relative with breast cancer (BC) (HR-2.19,
p
= 0.017) were positively associated with RRBM, whereas any previous benign breast biopsy was negatively associated (HR-0.48,
p
= 0.029) with performing RRBM.
Conclusions
RRBM is still infrequently elected by Israeli
BRCA1/BRCA2
mutation carriers, with married women with one relative with BC who have not undergone previous breast biopsy more likely to opt for RRBM.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-020-05949-z</identifier><identifier>PMID: 33000375</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Biopsy ; BRCA1 protein ; BRCA2 protein ; Breast cancer ; Cancer ; Cancer research ; Clinical Trial ; Gene mutations ; Genetic aspects ; Genotyping ; Mastectomy ; Medical centers ; Medicine ; Medicine & Public Health ; Mutation ; Oncology ; Oncology, Experimental ; Prevention ; Surgery</subject><ispartof>Breast cancer research and treatment, 2021, Vol.185 (2), p.391-399</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020</rights><rights>COPYRIGHT 2020 Springer</rights><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c388z-5d3fe7e1086a43f7949b1b442719bac42fb82cb008606d91d60208a770d9f6dc3</citedby><cites>FETCH-LOGICAL-c388z-5d3fe7e1086a43f7949b1b442719bac42fb82cb008606d91d60208a770d9f6dc3</cites><orcidid>0000-0002-6745-1733</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33000375$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Galmor, Lee</creatorcontrib><creatorcontrib>Bernstein-Molho, Rinat</creatorcontrib><creatorcontrib>Sklair-Levy, Miri</creatorcontrib><creatorcontrib>Madoursky-Feldman, Dana</creatorcontrib><creatorcontrib>Zippel, Dov</creatorcontrib><creatorcontrib>Laitman, Yael</creatorcontrib><creatorcontrib>Friedman, Eitan</creatorcontrib><title>Time trends in uptake rates of risk-reducing mastectomy in Israeli asymptomatic BRCA1 and BRCA2 mutation carriers</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><addtitle>Breast Cancer Res Treat</addtitle><description>Background
The rate of risk-reducing bilateral mastectomy (RRBM) among cancer-free Israeli female
BRCA1/BRCA2
mutation carriers was reportedly 13% in 2010. Current RRBM rates in Israel and factors seemingly associated with opting for RRBM were reevaluated.
Methods
Israeli female cancer-free
BRCA1/BRCA2
mutation carriers, who were followed at the high-risk clinic at Sheba Medical Center between January 2011 and April 2020 were eligible. Univariate Cox regression and log-rank test were used to study the crude association between potential predictors and performance of RRBM.
Results
Overall, 427 cancer-free
BRCA1
(
n
= 218) or
BRCA2
(
n
= 209) mutation carriers were included. Median age at genotyping was 33.6 years (interquartile range 26.8–41.8 years), median follow-up 4.4 years (range 0.1–7.6 years). Overall, 41/427 (9.6%) participants underwent RRBM, all of them within 5 years of genotyping. Being married (HR-2.57,
p
= 0.017) and having a first degree relative with breast cancer (BC) (HR-2.19,
p
= 0.017) were positively associated with RRBM, whereas any previous benign breast biopsy was negatively associated (HR-0.48,
p
= 0.029) with performing RRBM.
Conclusions
RRBM is still infrequently elected by Israeli
BRCA1/BRCA2
mutation carriers, with married women with one relative with BC who have not undergone previous breast biopsy more likely to opt for RRBM.</description><subject>Biopsy</subject><subject>BRCA1 protein</subject><subject>BRCA2 protein</subject><subject>Breast cancer</subject><subject>Cancer</subject><subject>Cancer research</subject><subject>Clinical Trial</subject><subject>Gene mutations</subject><subject>Genetic aspects</subject><subject>Genotyping</subject><subject>Mastectomy</subject><subject>Medical centers</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mutation</subject><subject>Oncology</subject><subject>Oncology, Experimental</subject><subject>Prevention</subject><subject>Surgery</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kt9rFDEQxxdR7Fn9B3yQgCC-bM2P3ST7eB5qC4VCqc8hm8xe0-4m1yT7cPfXm-tV24pIHjLMfL5DZvKtqvcEnxCMxZdEcNt0Naa4xm1Xot2LakFawWpBiXhZLTDhouYS86PqTUo3GONO4O51dcRYiZloF9XdlZsA5QjeJuQ8mjdZ3wKKOkNCYUDRpds6gp2N82s06ZTB5DBt9-xZihpGh3TaTpuS1NkZ9PVytSRIe3sfUTTNueSDR0bH6CCmt9WrQY8J3j3cx9XP79-uVqf1-cWPs9XyvDZMyl3dWjaAAIIl1w0bRJmvJ33TUEG6XpuGDr2kpseljrntiOVlD1ILgW03cGvYcfX50HcTw90MKavJJQPjqD2EOSnaNEIyyago6Me_0JswR19eVyjJpWy4oI_UWo-gnB9Cjtrsm6olb8tfyEbgQp38gyrHwuRM8DC4kn8m-PREcA16zNcpjPN-aek5SA-giSGlCIPaRDfpuFUEq70h1MEQqixC3RtC7Yrow8Nocz-B_SP57YACsAOQSsmvIT7O_p-2vwAe5L4G</recordid><startdate>2021</startdate><enddate>2021</enddate><creator>Galmor, Lee</creator><creator>Bernstein-Molho, Rinat</creator><creator>Sklair-Levy, Miri</creator><creator>Madoursky-Feldman, Dana</creator><creator>Zippel, Dov</creator><creator>Laitman, Yael</creator><creator>Friedman, Eitan</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6745-1733</orcidid></search><sort><creationdate>2021</creationdate><title>Time trends in uptake rates of risk-reducing mastectomy in Israeli asymptomatic BRCA1 and BRCA2 mutation carriers</title><author>Galmor, Lee ; Bernstein-Molho, Rinat ; Sklair-Levy, Miri ; Madoursky-Feldman, Dana ; Zippel, Dov ; Laitman, Yael ; Friedman, Eitan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c388z-5d3fe7e1086a43f7949b1b442719bac42fb82cb008606d91d60208a770d9f6dc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Biopsy</topic><topic>BRCA1 protein</topic><topic>BRCA2 protein</topic><topic>Breast cancer</topic><topic>Cancer</topic><topic>Cancer research</topic><topic>Clinical Trial</topic><topic>Gene mutations</topic><topic>Genetic aspects</topic><topic>Genotyping</topic><topic>Mastectomy</topic><topic>Medical centers</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mutation</topic><topic>Oncology</topic><topic>Oncology, Experimental</topic><topic>Prevention</topic><topic>Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Galmor, Lee</creatorcontrib><creatorcontrib>Bernstein-Molho, Rinat</creatorcontrib><creatorcontrib>Sklair-Levy, Miri</creatorcontrib><creatorcontrib>Madoursky-Feldman, Dana</creatorcontrib><creatorcontrib>Zippel, Dov</creatorcontrib><creatorcontrib>Laitman, Yael</creatorcontrib><creatorcontrib>Friedman, Eitan</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database (Proquest)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Galmor, Lee</au><au>Bernstein-Molho, Rinat</au><au>Sklair-Levy, Miri</au><au>Madoursky-Feldman, Dana</au><au>Zippel, Dov</au><au>Laitman, Yael</au><au>Friedman, Eitan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Time trends in uptake rates of risk-reducing mastectomy in Israeli asymptomatic BRCA1 and BRCA2 mutation carriers</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><addtitle>Breast Cancer Res Treat</addtitle><date>2021</date><risdate>2021</risdate><volume>185</volume><issue>2</issue><spage>391</spage><epage>399</epage><pages>391-399</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>Background
The rate of risk-reducing bilateral mastectomy (RRBM) among cancer-free Israeli female
BRCA1/BRCA2
mutation carriers was reportedly 13% in 2010. Current RRBM rates in Israel and factors seemingly associated with opting for RRBM were reevaluated.
Methods
Israeli female cancer-free
BRCA1/BRCA2
mutation carriers, who were followed at the high-risk clinic at Sheba Medical Center between January 2011 and April 2020 were eligible. Univariate Cox regression and log-rank test were used to study the crude association between potential predictors and performance of RRBM.
Results
Overall, 427 cancer-free
BRCA1
(
n
= 218) or
BRCA2
(
n
= 209) mutation carriers were included. Median age at genotyping was 33.6 years (interquartile range 26.8–41.8 years), median follow-up 4.4 years (range 0.1–7.6 years). Overall, 41/427 (9.6%) participants underwent RRBM, all of them within 5 years of genotyping. Being married (HR-2.57,
p
= 0.017) and having a first degree relative with breast cancer (BC) (HR-2.19,
p
= 0.017) were positively associated with RRBM, whereas any previous benign breast biopsy was negatively associated (HR-0.48,
p
= 0.029) with performing RRBM.
Conclusions
RRBM is still infrequently elected by Israeli
BRCA1/BRCA2
mutation carriers, with married women with one relative with BC who have not undergone previous breast biopsy more likely to opt for RRBM.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>33000375</pmid><doi>10.1007/s10549-020-05949-z</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-6745-1733</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6806 |
| ispartof | Breast cancer research and treatment, 2021, Vol.185 (2), p.391-399 |
| issn | 0167-6806 1573-7217 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2447838327 |
| source | Springer Link |
| subjects | Biopsy BRCA1 protein BRCA2 protein Breast cancer Cancer Cancer research Clinical Trial Gene mutations Genetic aspects Genotyping Mastectomy Medical centers Medicine Medicine & Public Health Mutation Oncology Oncology, Experimental Prevention Surgery |
| title | Time trends in uptake rates of risk-reducing mastectomy in Israeli asymptomatic BRCA1 and BRCA2 mutation carriers |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T22%3A59%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Time%20trends%20in%20uptake%20rates%20of%20risk-reducing%20mastectomy%20in%20Israeli%20asymptomatic%20BRCA1%20and%20BRCA2%20mutation%20carriers&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=Galmor,%20Lee&rft.date=2021&rft.volume=185&rft.issue=2&rft.spage=391&rft.epage=399&rft.pages=391-399&rft.issn=0167-6806&rft.eissn=1573-7217&rft_id=info:doi/10.1007/s10549-020-05949-z&rft_dat=%3Cgale_proqu%3EA651058470%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c388z-5d3fe7e1086a43f7949b1b442719bac42fb82cb008606d91d60208a770d9f6dc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2486884672&rft_id=info:pmid/33000375&rft_galeid=A651058470&rfr_iscdi=true |